Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
|Articles|October 1, 2010
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-10-01-2010
- Volume 22
- Issue 10
Quantitative open-access HPLC analysis: a new calibration approach
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high?performance liquid chromatography without having to prepare standards.
Advertisement
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high‑performance liquid chromatography without having to prepare standards. The authors discuss the approach taken to develop the tool, its associated protocols and how it can be used to calculate data.
Articles in this issue
almost 16 years ago
Validating Single-Use Systemsalmost 16 years ago
EGA Position On The EC's Proposal For A Falisifed Medicines Directivealmost 16 years ago
Green is the wordalmost 16 years ago
Using Certified Reference Material to Produce Compliant Water Purity Dataalmost 16 years ago
Newsalmost 16 years ago
The Pros And Cons Of Single-Use Systemsalmost 16 years ago
Europe: A Future Leader in Vaccines?almost 16 years ago
Developing A Quality Agreement Template For Single-Use Systemsalmost 16 years ago
Online Monitoring Of Continuous Hot Melt Extrusionalmost 16 years ago
An All-Round Excipient For Direct CompressionAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
Advertisement
Advertisement